{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:17Z","timestamp":1784613917299,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To perform signal mining of neuro-ophthalmic immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) using the FDA Adverse Event Reporting System (FAERS), and to synthesize their clinical manifestations and temporal patterns, thereby providing evidence-based insights for optimizing clinical drug safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reports of neuro-ophthalmic irAEs associated with ICIs were extracted from the FAERS (Q1 2011 to Q4 2025). Signal detection was performed using disproportionality analysis methodologies, specifically the Reporting Odds Ratio (ROR) and Information Component (IC) algorithms, with predefined statistical thresholds for signal significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 521 reports identified neuro-ophthalmic irAEs with ICIs as primary suspect drugs, predominantly affecting males and elderly patients At the High-Level Group Term (HLGT) level, positive signals were detected for pembrolizumab and avelumab. Preferred Term (PT) analysis revealed six significant signals, with eyelid ptosis being the most frequently reported event. The median time to onset was 28\u201338 days, with acute presentations (\u226424 hours post-infusion) observed for pembrolizumab and nivolumab; both agents exhibited elevated case fatality proportions, with a higher proportion of male patients among fatal cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study delineated potential neuro-ophthalmic positive disproportionality signals across seven ICIs, revealing demographic variations in signal reporting frequency with higher susceptibility among males and elderly patients. Pembrolizumab and avelumab were associated with higher reporting frequencies of neuro-ophthalmic adverse events, which were related to poor visual outcomes. Consequently, prompt recognition and management of neuro-ophthalmic irAEs are imperative to enhance ICI safety profiles in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1696617","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:15Z","timestamp":1784612175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["FAERS database reveals latent signals of neuro-ophthalmic toxicity associated with immune checkpoint inhibitors: feature mining and clinical warnings"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiewen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinan Shizhong People\u2019s Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongna","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: Promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol. Immunother"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/08820538.2024.2433636","article-title":"Ocular immune-related adverse events associated with Pd-1 inhibitors: From molecular mechanisms to clinical management","volume":"40","author":"Gong","year":"2024","journal-title":"Semin Ophthalmol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06350-4","article-title":"Neuro-ophthalmic complications of modern anti-cancer drugs","volume":"262","author":"Oskam","year":"2024","journal-title":"Graefe's. Arch For. Clin Exp Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocul. Immunol Inflammation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: Advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: A systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17925\/EE.2021.17.1.21","article-title":"Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies","volume":"17","author":"George","year":"2021","journal-title":"touchREV. Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol. Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.dib.2024.110062","article-title":"Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events","volume":"53","author":"Muller-Jensen","year":"2024","journal-title":"Data Brief"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.preteyeres.2019.04.002","article-title":"Immune privilege in corneal transplantation","volume":"72","author":"Hori","year":"2019","journal-title":"Prog Retin. Eye. Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-024-01336-z","article-title":"Update on neuro-ophthalmic manifestations of immune checkpoint inhibitors","volume":"24","author":"Chen","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the Fda adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2401","article-title":"Primary endpoint adjudication: Comparison between the expert committee and the regulatory Meddra\u00ae coding in the Mitra-Fr study","volume":"24","author":"Facile","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43441-022-00393-1","article-title":"Meddra labeling groupings to improve safety communication in product labels","volume":"57","author":"Gro\u00dfe-Michaelis","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/03946320251343943","article-title":"Evaluation of immune checkpoint inhibitor-associated hepatotoxic adverse events: A pharmacovigilance analysis based on the Faers database","volume":"39","author":"Chen","year":"2025","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1716090","article-title":"Unveiling the hidden cardiovascular risk of Sipuleucel-T: A pharmacovigilance analysis using the Fda adverse event reporting system, 2010-2025","volume":"16","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the Fda adverse event reporting system (Faers) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2020","journal-title":"Ocular. Immunol Inflammation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic. Inflammation Infect"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/wno.0000000000002330","article-title":"Immune checkpoint inhibitor-induced ocular myasthenia gravis: Case series and literature review","volume":"46","author":"Dezard","year":"2026","journal-title":"J Neuroophthalmol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5387\/fms.2019-01","article-title":"Eye diseases in women","volume":"65","author":"Kazama","year":"2019","journal-title":"Fukushima. J Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1939672","article-title":"The effect of patient sex on the efficacy and safety of anticancer immunotherapy","volume":"20","author":"Pala","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage Iii melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf008","article-title":"Immune-related adverse events in older adults receiving immune checkpoint inhibitors: A comprehensive analysis of the Food and Drug Administration adverse event reporting system","volume":"54","author":"Esen","year":"2025","journal-title":"Age. Ageing"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34395","article-title":"Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden","volume":"128","author":"Glanz","year":"2022","journal-title":"Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2023.11.011","article-title":"Iatrogenic affectation of ocular motility by immune checkpoint inhibitors","volume":"99","author":"Fernandez Jimenez-Ortiz","year":"2024","journal-title":"Arch Soc Esp. Oftalmol. (Engl. Ed)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/eb.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye. Brain"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: Long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2494995","article-title":"Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to Durvalumab","volume":"14","author":"Osborne","year":"2025","journal-title":"Oncoimmunology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-ophthalmic complications in patients treated with Ctla-4 and Pd-1\/Pd-L1 checkpoint blockade","volume":"41","author":"Sun","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2018.1490439","article-title":"Pembrolizumab and Epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia","volume":"38","author":"Hellman","year":"2019","journal-title":"Orbit"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.013","article-title":"Immune checkpoint inhibitors (Icis)-related ocular myositis","volume":"30","author":"Garibaldi","year":"2020","journal-title":"Neuromuscul. Disord"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112142-20240117-00030","article-title":"Research progress on the manifestations prevention and treatment of immune-related adverse events in the neuro-ophthalmic efferent system related to immune checkpoint inhibitors","volume":"61","author":"Jin","year":"2025","journal-title":"Zhonghua. Yan. Ke. Za. Zhi"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.81285","article-title":"A real-world pharmacovigilance study of Fda adverse event reporting system events for Avelumab","volume":"17","author":"He","year":"2025","journal-title":"Cureus"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: An update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (Dire) after discontinuation of immunotherapy: Diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-Pd-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (Mdx-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:17Z","timestamp":1784612177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1696617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1696617"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1696617","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1696617"}}